The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
- PMID: 10063482
- DOI: 10.1016/S0893-133X(98)00060-8
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
Abstract
Administration of noncompetitive NMDA/glutamate receptor antagonists, such as phencyclidine (PCP) and ketamine, to humans induces a broad range of schizophrenic-like symptomatology, findings that have contributed to a hypoglutamatergic hypothesis of schizophrenia. Moreover, a history of experimental investigations of the effects of these drugs in animals suggests that NMDA receptor antagonists may model some behavioral symptoms of schizophrenia in nonhuman subjects. In this review, the usefulness of PCP administration as a potential animal model of schizophrenia is considered. To support the contention that NMDA receptor antagonist administration represents a viable model of schizophrenia, the behavioral and neurobiological effects of these drugs are discussed, especially with regard to differing profiles following single-dose and long-term exposure. The neurochemical effects of NMDA receptor antagonist administration are argued to support a neurobiological hypothesis of schizophrenia, which includes pathophysiology within several neurotransmitter systems, manifested in behavioral pathology. Future directions for the application of NMDA receptor antagonist models of schizophrenia to preclinical and pathophysiological research are offered.
Similar articles
-
[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French.
-
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5. Int Rev Neurobiol. 2007. PMID: 17349858 Review.
-
[Receptor antagonist of NMDA and animal models of schizophrenia].Fa Yi Xue Za Zhi. 2009 Dec;25(6):443-6. Fa Yi Xue Za Zhi. 2009. PMID: 20225623 Review. Chinese.
-
Short and long term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment.J Neural Transm (Vienna). 2007;114(8):995-1001. doi: 10.1007/s00702-007-0668-x. Epub 2007 Mar 31. J Neural Transm (Vienna). 2007. PMID: 17401537
-
Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.Methods Find Exp Clin Pharmacol. 2007 May;29(4):291-301. doi: 10.1358/mf.2007.29.4.1075358. Methods Find Exp Clin Pharmacol. 2007. PMID: 17609743 Review.
Cited by
-
The dysconnection hypothesis (2016).Schizophr Res. 2016 Oct;176(2-3):83-94. doi: 10.1016/j.schres.2016.07.014. Epub 2016 Jul 20. Schizophr Res. 2016. PMID: 27450778 Free PMC article. Review.
-
Drug models of schizophrenia.Ther Adv Psychopharmacol. 2015 Feb;5(1):43-58. doi: 10.1177/2045125314557797. Ther Adv Psychopharmacol. 2015. PMID: 25653831 Free PMC article. Review.
-
DISC1 as a therapeutic target for mental illnesses.Expert Opin Ther Targets. 2012 Dec;16(12):1151-60. doi: 10.1517/14728222.2012.719879. Epub 2012 Nov 6. Expert Opin Ther Targets. 2012. PMID: 23130881 Free PMC article. Review.
-
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.Neuron. 2013 Apr 10;78(1):81-93. doi: 10.1016/j.neuron.2013.02.011. Neuron. 2013. PMID: 23583108 Free PMC article.
-
The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.Psychopharmacology (Berl). 2015 Nov;232(21-22):4059-83. doi: 10.1007/s00213-015-3954-6. Epub 2015 Jun 14. Psychopharmacology (Berl). 2015. PMID: 26070547 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
